2021 CSCO 肿瘤相关性贫血临床实践指南

2021-08-01 中国临床肿瘤学会 人民卫生出版社

肿瘤相关性贫血(cancer related anemia,CRA)主要是指肿瘤患者在其疾病的发展过程中以及治疗过程中发生的贫血,是恶性肿瘤常见的伴随疾病之一。

中文标题:

2021 CSCO 肿瘤相关性贫血临床实践指南

发布机构:

中国临床肿瘤学会

发布日期:

2021-08-01

简要介绍:

肿瘤相关性贫血(cancer related anemia,CRA)主要是指肿瘤患者在其疾病的发展过程中以及治疗过程中发生的贫血,是恶性肿瘤常见的伴随疾病之一。其发生原因多样,包括肿瘤本身所致、机体的营养吸收障碍以及长期接受治疗所致。统计数据表明,约有30-90%的肿瘤患者会出现贫血。高达92.84%的CRA患者未给予任何纠正贫血的措施和治疗。由此可见,CRA发生率高,但治疗率低,应该引起足够的重视。

相关资料下载:
[AttachmentFileName(sort=1, fileName=2021CSCO肿瘤相关性贫血临床实践指南.pdf)] GetToolGuiderByIdResponse(projectId=1, id=0f0241c002293a44, title=2021 CSCO 肿瘤相关性贫血临床实践指南, enTitle=, guiderFrom=人民卫生出版社, authorId=0, author=, summary=肿瘤相关性贫血(cancer related anemia,CRA)主要是指肿瘤患者在其疾病的发展过程中以及治疗过程中发生的贫血,是恶性肿瘤常见的伴随疾病之一。, cover=https://img.medsci.cn/20211216/1639669903764_5579292.jpg, journalId=0, articlesId=null, associationId=863, associationName=中国临床肿瘤学会, associationIntro=null, copyright=0, guiderPublishedTime=Sun Aug 01 00:00:00 CST 2021, originalUrl=, linkOutUrl=, content=<p><span style="color: #222222;">肿瘤相关性贫血(cancer related anemia,CRA)主要是指肿瘤患者在其疾病的发展过程中以及治疗过程中发生的贫血,是恶性肿瘤常见的伴随疾病之一。其发生原因多样,包括肿瘤本身所致、机体的营养吸收障碍以及长期接受治疗所致。统计数据表明,约有30-90%的肿瘤患者会出现贫血。高达92.84%的CRA患者未给予任何纠正贫血的措施和治疗。由此可见,CRA发生率高,但治疗率低,应该引起足够的重视。</span></p>, tagList=[TagDto(tagId=60046, tagName=肿瘤相关性贫血)], categoryList=[CategoryDto(categoryId=5, categoryName=肿瘤, tenant=100), CategoryDto(categoryId=21, categoryName=血液科, tenant=100), CategoryDto(categoryId=85, categoryName=指南&解读, tenant=100), CategoryDto(categoryId=21100, categoryName=达仁堂循证e学界, tenant=100)], articleKeywordId=0, articleKeyword=, articleKeywordNum=6, guiderKeywordId=60046, guiderKeyword=肿瘤相关性贫血, guiderKeywordNum=6, haveAttachments=1, attachmentList=null, guiderType=0, guiderArea=指南, guiderLanguage=0, guiderRegion=3, opened=0, paymentType=, paymentAmount=10, recommend=0, recommendEndTime=null, sticky=0, stickyEndTime=null, allHits=3259, appHits=215, showAppHits=0, pcHits=948, showPcHits=3044, likes=4, shares=31, comments=22, approvalStatus=1, publishedTime=Thu Dec 16 23:45:10 CST 2021, publishedTimeString=2021-08-01, pcVisible=1, appVisible=1, editorId=5579292, editor=FUNNYMAN, waterMark=0, formatted=0, memberCards=[], isPrivilege=0, deleted=0, version=2, createdBy=null, createdName=FUNNYMAN, createdTime=Thu Dec 16 23:56:22 CST 2021, updatedBy=5579292, updatedName=FUNNYMAN, updatedTime=Sat Jan 06 15:08:33 CST 2024, courseDetails=[], otherVersionGuiders=[], isGuiderMember=false, ipAttribution=, attachmentFileNameList=[AttachmentFileName(sort=1, fileName=2021CSCO肿瘤相关性贫血临床实践指南.pdf)])
2021CSCO肿瘤相关性贫血临床实践指南.pdf
下载请点击:
评论区 (19)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=2163325, encodeId=08e1216332554, content=感谢分享, beContent=null, objectType=guider, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=20729020134, createdName=ms8000000819646347, createdTime=Tue Oct 17 14:51:38 CST 2023, time=2023-10-17, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2125690, encodeId=51b22125690d7, content=评论的积分吗?, beContent=null, objectType=guider, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=86138632336, createdName=ms8000001846778698, createdTime=Thu Apr 13 15:19:24 CST 2023, time=2023-04-13, status=1, ipAttribution=陕西省), GetPortalCommentsPageByObjectIdResponse(id=2092455, encodeId=01d220924552b, content=学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c78f8353119, createdName=ms6000000074653151, createdTime=Sat Oct 08 11:03:32 CST 2022, time=2022-10-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1249356, encodeId=0e001249356b4, content=指南指导治疗<a href='/topic/show?id=c14d5638971' target=_blank style='color:#2F92EE;'>#指南#</a> , beContent=null, objectType=guider, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=56389, encryptionId=c14d5638971, topicName=指南)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c9c48225867, createdName=ms4000000261661286, createdTime=Fri Sep 16 16:00:49 CST 2022, time=2022-09-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1248130, encodeId=69d612481304d, content=学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=be1a8317767, createdName=ms3000001946682904, createdTime=Fri Sep 09 15:37:25 CST 2022, time=2022-09-09, status=1, ipAttribution=)]
    2023-10-17 ms8000000819646347 来自江苏省

    感谢分享

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=2163325, encodeId=08e1216332554, content=感谢分享, beContent=null, objectType=guider, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=20729020134, createdName=ms8000000819646347, createdTime=Tue Oct 17 14:51:38 CST 2023, time=2023-10-17, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2125690, encodeId=51b22125690d7, content=评论的积分吗?, beContent=null, objectType=guider, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=86138632336, createdName=ms8000001846778698, createdTime=Thu Apr 13 15:19:24 CST 2023, time=2023-04-13, status=1, ipAttribution=陕西省), GetPortalCommentsPageByObjectIdResponse(id=2092455, encodeId=01d220924552b, content=学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c78f8353119, createdName=ms6000000074653151, createdTime=Sat Oct 08 11:03:32 CST 2022, time=2022-10-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1249356, encodeId=0e001249356b4, content=指南指导治疗<a href='/topic/show?id=c14d5638971' target=_blank style='color:#2F92EE;'>#指南#</a> , beContent=null, objectType=guider, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=56389, encryptionId=c14d5638971, topicName=指南)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c9c48225867, createdName=ms4000000261661286, createdTime=Fri Sep 16 16:00:49 CST 2022, time=2022-09-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1248130, encodeId=69d612481304d, content=学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=be1a8317767, createdName=ms3000001946682904, createdTime=Fri Sep 09 15:37:25 CST 2022, time=2022-09-09, status=1, ipAttribution=)]
    2023-04-13 ms8000001846778698 来自陕西省

    评论的积分吗?

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=2163325, encodeId=08e1216332554, content=感谢分享, beContent=null, objectType=guider, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=20729020134, createdName=ms8000000819646347, createdTime=Tue Oct 17 14:51:38 CST 2023, time=2023-10-17, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2125690, encodeId=51b22125690d7, content=评论的积分吗?, beContent=null, objectType=guider, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=86138632336, createdName=ms8000001846778698, createdTime=Thu Apr 13 15:19:24 CST 2023, time=2023-04-13, status=1, ipAttribution=陕西省), GetPortalCommentsPageByObjectIdResponse(id=2092455, encodeId=01d220924552b, content=学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c78f8353119, createdName=ms6000000074653151, createdTime=Sat Oct 08 11:03:32 CST 2022, time=2022-10-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1249356, encodeId=0e001249356b4, content=指南指导治疗<a href='/topic/show?id=c14d5638971' target=_blank style='color:#2F92EE;'>#指南#</a> , beContent=null, objectType=guider, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=56389, encryptionId=c14d5638971, topicName=指南)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c9c48225867, createdName=ms4000000261661286, createdTime=Fri Sep 16 16:00:49 CST 2022, time=2022-09-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1248130, encodeId=69d612481304d, content=学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=be1a8317767, createdName=ms3000001946682904, createdTime=Fri Sep 09 15:37:25 CST 2022, time=2022-09-09, status=1, ipAttribution=)]
    2022-10-08 ms6000000074653151

    学习

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=2163325, encodeId=08e1216332554, content=感谢分享, beContent=null, objectType=guider, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=20729020134, createdName=ms8000000819646347, createdTime=Tue Oct 17 14:51:38 CST 2023, time=2023-10-17, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2125690, encodeId=51b22125690d7, content=评论的积分吗?, beContent=null, objectType=guider, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=86138632336, createdName=ms8000001846778698, createdTime=Thu Apr 13 15:19:24 CST 2023, time=2023-04-13, status=1, ipAttribution=陕西省), GetPortalCommentsPageByObjectIdResponse(id=2092455, encodeId=01d220924552b, content=学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c78f8353119, createdName=ms6000000074653151, createdTime=Sat Oct 08 11:03:32 CST 2022, time=2022-10-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1249356, encodeId=0e001249356b4, content=指南指导治疗<a href='/topic/show?id=c14d5638971' target=_blank style='color:#2F92EE;'>#指南#</a> , beContent=null, objectType=guider, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=56389, encryptionId=c14d5638971, topicName=指南)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c9c48225867, createdName=ms4000000261661286, createdTime=Fri Sep 16 16:00:49 CST 2022, time=2022-09-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1248130, encodeId=69d612481304d, content=学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=be1a8317767, createdName=ms3000001946682904, createdTime=Fri Sep 09 15:37:25 CST 2022, time=2022-09-09, status=1, ipAttribution=)]
    2022-09-16 ms4000000261661286

    指南指导治疗#指南#

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=2163325, encodeId=08e1216332554, content=感谢分享, beContent=null, objectType=guider, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=20729020134, createdName=ms8000000819646347, createdTime=Tue Oct 17 14:51:38 CST 2023, time=2023-10-17, status=1, ipAttribution=江苏省), GetPortalCommentsPageByObjectIdResponse(id=2125690, encodeId=51b22125690d7, content=评论的积分吗?, beContent=null, objectType=guider, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=86138632336, createdName=ms8000001846778698, createdTime=Thu Apr 13 15:19:24 CST 2023, time=2023-04-13, status=1, ipAttribution=陕西省), GetPortalCommentsPageByObjectIdResponse(id=2092455, encodeId=01d220924552b, content=学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c78f8353119, createdName=ms6000000074653151, createdTime=Sat Oct 08 11:03:32 CST 2022, time=2022-10-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1249356, encodeId=0e001249356b4, content=指南指导治疗<a href='/topic/show?id=c14d5638971' target=_blank style='color:#2F92EE;'>#指南#</a> , beContent=null, objectType=guider, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=56389, encryptionId=c14d5638971, topicName=指南)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c9c48225867, createdName=ms4000000261661286, createdTime=Fri Sep 16 16:00:49 CST 2022, time=2022-09-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1248130, encodeId=69d612481304d, content=学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=be1a8317767, createdName=ms3000001946682904, createdTime=Fri Sep 09 15:37:25 CST 2022, time=2022-09-09, status=1, ipAttribution=)]
    2022-09-09 ms3000001946682904

    学习

    0

拓展阅读

肿瘤相关性贫血中医药防治专家共识

中华中医药学会(CACM,China Association of Chinese Medcine) · 2021-01-30